Trial Profile

GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Clarithromycin; Dexamethasone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms GEM-CLARIDEX

Most Recent Events

13 Dec 2022 Results of an analysis assessing immune biomarkers in elderly newly diagnosed multiple myeloma patients treated with Lenalidomide and Dexamethasone presented at the 64th American Society of Hematology Annual Meeting and Exposition
17 Jan 2022 Planned primary completion date changed from 1 May 2021 to 1 Oct 2024.
14 Apr 2021 Planned End Date changed from 1 Jan 2022 to 10 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com